GraceFinance · Source-backed public company research
Kura Oncology, Inc. (KURA)
Nasdaq · Manufacturing · Pharmaceutical Preparations
Core research established · 4/4 core data layers currently established
What Kura Oncology, Inc. does
Overview We are a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Since our founding in 2014, we have transformed from a research and development company to a fully-integrated commercial-stage organization with a diversified pipeline of product candidates. Our pipeline consists of small molecules designed to target cancer signaling pathways and address significant unmet needs in oncology and hematology. 2025 was a pivotal year for our company.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.